TY - JOUR
T1 - Brain Health Services
T2 - organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6
AU - Altomare, Daniele
AU - Molinuevo, José Luis
AU - Ritchie, Craig
AU - Ribaldi, Federica
AU - Carrera, Emmanuel
AU - Dubois, Bruno
AU - Jessen, Frank
AU - McWhirter, Laura
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Vellas, Bruno
AU - Démonet, Jean-François
AU - Frisoni, Giovanni B.
AU - on behalf of the European Task Force for Brain Health Services
AU - Abramowicz, Marc
AU - Altomare, Daniele
AU - Barkhof, Frederik
AU - Berthier, Marcelo
AU - Bieler, Melanie
AU - Blennow, Kaj
AU - Brayne, Carol
AU - Brioschi, Andrea
AU - Chételat, Gael
AU - Csajka, Chantal
AU - Demonet, Jean-François
AU - Dodich, Alessandra
AU - Garibotto, Valentina
AU - Georges, Jean
AU - Hurst, Samia
AU - Kivipelto, Miia
AU - Llewellyn, David
AU - Milne, Richard
AU - Minguillón, Carolina
AU - Miniussi, Carlo
AU - Nilsson, Peter M.
AU - Ranson, Janice
AU - Solomon, Alina
AU - van der Flier, Wiesje
AU - van Duijn, Cornelia
AU - Visser, Leonie
N1 - Funding Information:
GBF received funding by: the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) “European Prevention of Alzheimer’s Dementia consortium” (EPAD, grant agreement number: 115736) and “Amyloid Imaging to Prevent Alzheimer’s Disease” (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation: “Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): correlation with clinical features and in vivo neuropathology” (grant number: 320030_182772).
Funding Information:
JFD has received consultancy fees from Biogen and OM Pharma; unrestricted grants from OM Pharma; and has collaboration agreements with Siemens and MindMaze.
Funding Information:
European Task Force for Brain Health Services (in alphabetical order): Marc ABRAMOWICZ, Daniele ALTOMARE, Frederik BARKHOF, Marcelo BERTHIER, Melanie BIELER, Kaj BLENNOW, Carol BRAYNE, Andrea BRIOSCHI, Emmanuel CARRERA, Gael CH?TELAT, Chantal CSAJKA, Jean-Fran?ois DEMONET, Alessandra DODICH, Bruno DUBOIS, Giovanni B. FRISONI, Valentina GARIBOTTO, Jean GEORGES, Samia HURST, Frank JESSEN, Miia KIVIPELTO, David LLEWELLYN, Laura McWHIRTER, Richard MILNE, Carolina MINGUILL?N, Carlo MINIUSSI, Jos? Luis MOLINUEVO, Peter M NILSSON, Janice RANSON, Federica RIBALDI, Craig RITCHIE, Philip SCHELTENS, Alina SOLOMON, Wiesje VAN DER FLIER, Cornelia VAN DUIJN, Bruno VELLAS, Leonie VISSER.
Funding Information:
GBF reports grants from Alzheimer Forum Suisse, Académie Suisse des Sciences Médicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l’Alzheimer, IXICO, Merz Pharma, Nestlé, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer’s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.
Funding Information:
This paper was the product of a workshop funded by the Swiss National Science Foundation entitled “Dementia Prevention Services” (grant number: IZSEZ0_193593).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Dementia has a devastating impact on the quality of life of patients and families and comes with a huge cost to society. Dementia prevention is considered a public health priority by the World Health Organization. Delaying the onset of dementia by treating associated risk factors will bring huge individual and societal benefit. Empirical evidence suggests that, in higher-income countries, dementia incidence is decreasing as a result of healthier lifestyles. This observation supports the notion that preventing dementia is possible and that a certain degree of prevention is already in action. Further reduction of dementia incidence through deliberate prevention plans is needed to counteract its growing prevalence due to increasing life expectancy. An increasing number of individuals with normal cognitive performance seek help in the current memory clinics asking an evaluation of their dementia risk, preventive interventions, or interventions to ameliorate their cognitive performance. Consistent evidence suggests that some of these individuals are indeed at increased risk of dementia. This new health demand asks for a shift of target population, from patients with cognitive impairment to worried but cognitively unimpaired individuals. However, current memory clinics do not have the programs and protocols in place to deal with this new population. We envision the development of new services, henceforth called Brain Health Services, devoted to respond to demands from cognitively unimpaired individuals concerned about their risk of dementia. The missions of Brain Health Services will be (i) dementia risk profiling, (ii) dementia risk communication, (iii) dementia risk reduction, and (iv) cognitive enhancement. In this paper, we present the organizational and structural challenges associated with the set-up of Brain Health Services.
AB - Dementia has a devastating impact on the quality of life of patients and families and comes with a huge cost to society. Dementia prevention is considered a public health priority by the World Health Organization. Delaying the onset of dementia by treating associated risk factors will bring huge individual and societal benefit. Empirical evidence suggests that, in higher-income countries, dementia incidence is decreasing as a result of healthier lifestyles. This observation supports the notion that preventing dementia is possible and that a certain degree of prevention is already in action. Further reduction of dementia incidence through deliberate prevention plans is needed to counteract its growing prevalence due to increasing life expectancy. An increasing number of individuals with normal cognitive performance seek help in the current memory clinics asking an evaluation of their dementia risk, preventive interventions, or interventions to ameliorate their cognitive performance. Consistent evidence suggests that some of these individuals are indeed at increased risk of dementia. This new health demand asks for a shift of target population, from patients with cognitive impairment to worried but cognitively unimpaired individuals. However, current memory clinics do not have the programs and protocols in place to deal with this new population. We envision the development of new services, henceforth called Brain Health Services, devoted to respond to demands from cognitively unimpaired individuals concerned about their risk of dementia. The missions of Brain Health Services will be (i) dementia risk profiling, (ii) dementia risk communication, (iii) dementia risk reduction, and (iv) cognitive enhancement. In this paper, we present the organizational and structural challenges associated with the set-up of Brain Health Services.
KW - Aging
KW - Alzheimer’s disease
KW - Brain Health Services
KW - Cognitive enhancement
KW - Dementia
KW - Dementia risk
KW - Personalized medicine
KW - Prevention
KW - Risk communication
KW - Risk reduction
UR - http://www.scopus.com/inward/record.url?scp=85116911722&partnerID=8YFLogxK
U2 - 10.1186/s13195-021-00827-2
DO - 10.1186/s13195-021-00827-2
M3 - Review article
C2 - 34635163
VL - 13
JO - Alzheimer's Research & Therapy
JF - Alzheimer's Research & Therapy
SN - 1758-9193
IS - 1
M1 - 168
ER -